Cologuard Plus launches in the US with Medicare coverage and 40% fewer false positives

Abbott Laboratories/Cologuard

Exact Sciences began selling Cologuard Plus, mailed directly to patients like the original. It cuts false positives by 40% versus the first Cologuard, which had completed more than 19 million screenings over a decade.

• Covered by Medicare as a recommended screening option.
• 40% fewer false positives than the original Cologuard.
• 95% sensitivity for cancer, 74% for high-grade dysplasia.
• Over 19 million Cologuard screenings completed in the previous ten years.